Karyopharm Therapeutics | KPTI - Cash And Equivalent


Karyopharm Therapeutics reported $90.85M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Abbott USD 6.8B 1.72B Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Takeda JPY 460.98B 134.07B Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Xencor USD 44.66M 30.49M Jun/2026